Ukrainian government to impose state control for drug prices in domestic market

18 November 2014

The Ukraine government has officially imposed state control on the prices of drugs in the domestic market, according to press service of the Ministry of Health.

According to decisions of the local government, retail markups in the country’s pharmaceutical market will vary in the range of 10-25%, both for domestic and imported drugs. So far, such markups have reached 100-170% and the government did not have efficient means to restrict the growth of prices.

According to Oleksandr Sych, Ukraine’s Vice Prime Minister, the introduction of state regulation over pricing in the national pharmaceutical market will make drugs more affordable for the local population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >